Praxis Precision Medicines (PRAX)
(Delayed Data from NSDQ)
$47.79 USD
-3.30 (-6.46%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $47.71 -0.08 (-0.17%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PRAX 47.79 -3.30(-6.46%)
Will PRAX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PRAX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PRAX
Praxis Precision Medicines, Inc. (PRAX) Reports Q4 Loss, Tops Revenue Estimates
IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
PRAX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Ensign Group (ENSG) Q4 Earnings and Revenues Beat Estimates
Praxis Precision Medicines, Inc. (PRAX) Reports Q3 Loss, Misses Revenue Estimates
Other News for PRAX
Praxis Precision Medicine (PRAX): HC Wainwright & Co. Raises Price Target | PRAX Stock News
PRAX Price Target Increased by H.C. Wainwright Following Positive Trial Results
Praxis Precision Medicines to Participate in Upcoming Fireside Chat | PRAX Stock News
Praxis Precision price target raised by $10 at H.C. Wainwright, here's why
Praxis Precision Medicines Inc (PRAX) Q2 2025 Earnings Call Highlights: Vormatrigine Shows ...